Publications by authors named "Jason Bradt"
Article Synopsis
- Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) is a rare genetic disease that disrupts the immune system, causing various symptoms that usually begin in childhood.
- In a phase III clinical trial, a drug called leniolisib was shown to effectively reduce lymph node swelling and increase naïve B cell levels in both adolescents and adults with APDS compared to those given a placebo.
- The study found that leniolisib was well-tolerated across age groups and suggests it could be a promising treatment option for managing APDS by addressing the underlying cause rather than just the symptoms.
Article Synopsis
- Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) is a genetic immune disorder that leads to frequent infections and abnormal immune cell growth, but treatment with leniolisib, a selective PI3Kδ inhibitor, has shown promising results.
- In a 6-year follow-up study of 6 adult patients who received leniolisib, improvements were noted in health-related quality of life (HRQoL), with most patients reporting better physical capabilities and reduced medication usage.
- Overall immune responses improved, with significant reductions in certain immune cell types and fewer infections, supporting leniolisib as a viable long-term treatment for APDS, while adverse events were mostly mild.
Interim analysis: Open-label extension study of leniolisib for patients with APDS.
J Allergy Clin Immunol
January 2024
Article Synopsis
- Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) is a genetic condition characterized by overactive PI3Kδ, leading to immune issues like recurrent infections and autoimmunity.
- Leniolisib, a targeted inhibitor of PI3Kδ, showed promise in improving immune function and reducing complications like lymphoproliferation in patients with APDS over a 12-week period.
- An ongoing study involving 37 patients showed that most experienced mild to moderate side effects, but leniolisib significantly decreased infection rates and improved overall health, with many patients needing less immunoglobulin therapy.
Article Synopsis
- Activated phosphoinositide 3-kinase delta syndrome (APDS) is an immune disorder that leads to various health issues like infections and autoimmunity due to overactive PI3Kδ signaling.
- A phase 3 clinical trial tested leniolisib, a specific inhibitor of PI3Kδ, on 31 patients aged 12 and older, comparing its effects against a placebo over 12 weeks.
- Results showed that leniolisib significantly reduced lymph node size and increased naïve B cells, indicating improved immune function, while also being well-tolerated with fewer adverse events compared to placebo.
Objectives: To examine potentially inappropriate medication (PIM) use in older adults initiating an antimuscarinic medication for the treatment of overactive bladder (OAB).
Design: Retrospective database analysis.
Setting: Medical and pharmacy claims data.
Purpose: Bladder dysfunction influences recovery of urinary continence after radical prostatectomy. We performed a multicenter, randomized, double-blind study evaluating solifenacin vs placebo on return to continence in patients who were still incontinent 7 to 21 days after catheter removal after robot-assisted radical prostatectomy.
Materials And Methods: A wireless personal digital assistant was given to patients the day of catheter removal.
Purpose: The impact of i.v. drug delivery via point-of-care (POC)-activated and closed systems versus traditional manual admixture systems on the risk of hospital-acquired bloodstream infection (BSI) is examined.
View Article and Find Full Text PDF